

Company Focus

14 November 2007 | 12 pages

ITC (ITC.BO)

Buy: Fundamentals Improving Amid Attractive Valuations

- Buying opportunity Cigarette volumes are stabilizing and could surprise positively, personal care expansion is unlikely to lead to excessive "cash burn" and we expect a benign tax environment ahead. Against this backdrop, ITC's stock is trading at the lower end of its historical trading band (17x FY09E P/E), providing a favorable risk-reward trade off. Buy (1L).
- Cigarette volume decline arrested Our discussions with the management suggest that the cigarette volume decline has been arrested. Volumes have been flat over the last 2 months, after declining about 3.5% in 2QFY08E. Product mix has also not deteriorated, as volumes have declined mainly at the lower-end brands. We expect cigarette volumes to start growing from 4QFY08.
- Personal care rolling out ITC is looking to ramp up its personal care presence (soaps and shampoos currently) over the next 8 quarters. Existing consumer businesses (excluding 'Bingo') are on course to break even by 4QFY08. According to management, while marketing spends behind the personal care business will increase, they are unlikely to be "excessive."
- Expect benign tax environment Consensus on VAT took two years to build, and it seems unlikely that the rate would be revised anytime soon. Also, VAT being an ad-valorem tax linked to gross sales, state collections will likely continue to increase, keeping the incentive for a rate hike muted. In addition, a possible decline in volumes in FY08E is likely to keep the excise rate increased in-line with recent hikes (5%-6%).

Statistical Abstract

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2006A	22,354	6.00	10.0	30.5	7.5	26.4	1.5
2007A	27,000	7.18	19.5	25.5	6.6	27.7	1.7
2008E	33,176	8.82	22.9	20.8	5.6	29.2	1.9
2009E	40,466	10.76	22.0	17.0	4.7	30.2	2.3
2010E	49,613	13.19	22.6	13.9	4.0	31.1	2.7

Source: Powered by dataCentral

See Appendix A-1 for Analyst Certification and important disclosures.

Buy/Low Risk	1L
Price (14 Nov 07)	Rs183.20
Target price	Rs215.00
Expected share price return	17.4%
Expected dividend yield	1.9%
Expected total return	19.3%
Market Cap	Rs689,674M
	US\$17,580M

Price Performance (RIC: ITC.BO, BB: ITC IN)



Princy Singh¹

+91-22-6631-9871 princy.singh@citi.com

Pragati Khadse¹

+91-22-6631-9856 pragati.khadse@citi.com

Aditya Mathur¹

aditya.mathur@citi.com

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

¹Citigroup Global Markets India Private Limited

Fiscal year end 31-Mar	2006	2007	2008E	2009E	2010E
Valuation Ratios					
P/E adjusted (x)	30.5	25.5	20.8	17.0	13.9
EV/EBITDA adjusted (x)	19.5	16.4	13.3	10.6	8.4
P/BV (x)	7.5	6.6	5.6	4.7	4.0
Dividend yield (%)	1.5	1.7	1.9	2.3	2.7
Per Share Data (Rs)					
EPS adjusted	6.00	7.18	8.82	10.76	13.19
EPS reported	6.00	7.18	8.82	10.76	13.19
BVPS	24.34	27.74	32.57	38.58	46.13
DPS	2.67	3.10	3.54	4.20	5.00
Profit & Loss (RsM)					
Net sales	97,905	123,693	143,809	168,680	198,073
Operating expenses	-67,955	-87,758	-99,750	-114,208	-130,533
EBIT	29,950	35,935	44,060	54,472	67,539
Net interest expense	-119	-33	-30	-30	-30
Non-operating/exceptionals	2,411	3,365	3,365	3,366	3,366
Pre-tax profit	32,242	39,267	47,395	57,808	70,875 -21,262
Tax Extraord./Min.Int./Pref.div.	-9,888 0	-12,267 0	-14,218 0	-17,342 0	-21,262
Reported net income	22,354	27,000	33,176	40,466	49,613
Adjusted earnings	22,354	27,000	33,176	40,466	49,613
Adjusted EBITDA	33,274	39,564	48,333	59,334	72,782
Growth Rates (%)	,	,	,	,	,
Sales	30.9	26.3	16.3	17.3	17.4
EBIT adjusted	29.1	20.0	22.6	23.6	24.0
EBITDA adjusted	26.4	18.9	22.2	22.8	22.7
EPS adjusted	10.0	19.5	22.9	22.0	22.6
Cash Flow (RsM)					
Operating cash flow	19,507	22,952	31,908	42,757	52,049
Depreciation/amortization	3,323	3,629	4,274	4,862	5,242
Net working capital	-2,739	-7,677	-5,542	-2,571	-2,806
Investing cash flow	-1,797	-11,178	-16,000	-16,000	-16,000
Capital expenditure	-5,382	-15,299	-7,000	-7,000	-7,000
Acquisitions/disposals	0	0 10.050	0	0	0
Financing cash flow Borrowings	-11,201 -1,256	-10,950 812	-17,038 -2,009	- 17,832 0	- 21,228 0
Dividends paid	-11,256	-13,645	-15,030	-17,832	-21,228
Change in cash	6,509	-13,045 824	-1,131	8,925	14,821
Balance Sheet (RsM)	-,			- /	7-
Total assets	120 040	140 604	172 052	202 116	240 222
Cash & cash equivalent	130,840 9,110	149,684 9,544	172,952 8,413	203,116 17,337	240,333 32,157
Accounts receivable	5,480	9,344 6,367	9,850	11,553	13,567
Net fixed assets	44,051	56,109	58,835	60,973	62,731
Total liabilities	40,226	45,313	50,434	57,965	66,799
Accounts payable	21,890	23,848	27,122	31,069	35,527
Total Debt	1,197	2,009	, 0	0	0
Shareholders' funds	90,615	104,371	122,517	145,150	173,534
Profitability/Solvency Ratios (%)					
EBITDA margin adjusted	34.0	32.0	33.6	35.2	36.7
ROE adjusted	26.4	27.7	29.2	30.2	31.1
ROIC adjusted	42.5	39.6	40.5	46.3	54.5
Net debt to equity	-8.7	-7.2	-6.9	-11.9	-18.5
Total debt to capital	1.3	1.9	0.0	0.0	0.0

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Cigarette Volumes Stabilizing

Our discussions with ITC management suggest that the cigarette volume trend continues to improve. Post 3.5% decline in 2QFY08, volumes have now started to stabilize and have not declined over the last 8 quarters. Cigarette volumes have surprised positively, demonstrating strong resilience after 20% price hikes affected by ITC in April-May following imposition of VAT at 12.5% rate. We expect volumes to start to grow again by 4QFY08. We are currently assuming 2% volume decline for FY08E. Given that overall volumes have fared better in 1HFY08, compared to our FY08 estimates, we believe that there are strong chances of positive surprises on volumes ahead. We enumerate below sensitivity of ITC's earnings to cigarette volumes:

Cigarette Volume Growth (%)	PAT (Rsm)	% Change from Base Case
-4.0	31,363.8	-5.5
-3.0	32,270.0	-2.7
Base Case -2.0	33,176.2	0.0
-1.0	34,082.0	2.7
0.0	34,988.5	5.5
1.0	35,894.6	8.2
2.0	36,800.8	10.9
3.0	37,706.9	13.7
4.0	38,613.1	16.4

Figure 1. FY08E Earnings Sensitivity to Cigarette Volume Growth

Product Mix Stable, Margins Could Surprise

According to management, volume declines have mainly been at the lower-end brands (non-filter cigarettes), and product mix has not deteriorated. Given that price hikes are heavily loaded in favor of the mid-segment brands, we believe that stable product mix bodes well for cigarette business margins. Even if consumers were to trade down, typically it would be confined within the same segment, i.e., a regular size filter smoker is unlikely to shift toward plains or micros, but likely to shift to a cheaper brand within the regular size cigarettes. Our price hike analysis suggests that such trading down could potentially benefit margins. This could particularly play out in the longs segment, which accounts for 65% of overall volumes. In this segment, prices have been hiked by 15% for the most expensive brand (Gold Flake Premium), but increased by 42%-74% for cheaper brands like Bristol and Flake filters. While we do not have specific margin profile of each brand, we believe that given the extent of the price hike differentials, it is very likely that trading down would enhance margins.

Figure 2. ITC – Segment Wise Price Hike Analysis

Brand / Segment	Old per stick price (Rs)	New per stick price (Rs)	Inc. in price per stick (Rs)	FYO7 per stick excise (Rs)	FYO8 per stick excise (Rs)	FYO8 VAT per stick (Rs)	FY07 net realization per stick (Rs)	FY08 net realization per stick (Rs)	Change in net realization (Rs)	in net
KSFT - 10% of volumes										
555 FT Kings	4.00	4.50	0.50	1.725	1.811	0.45	1.88	1.78	-0.09	-4.8
B. & H. Special	4.00	4.50	0.50	1.725	1.811	0.45	1.88	1.78	-0.09	-4.8
B. & H. Lights	4.00	4.50	0.50	1.725	1.811	0.45	1.88	1.78	-0.09	-4.8
India FT. Kings	4.50	5.00	0.50	1.725	1.811	0.51	2.33	2.18	-0.14	-6.1
India Kings Lights	4.50	5.00	0.50	1.725	1.811	0.51	2.33	2.18	-0.14	-6.1
Classic FT Kings	3.50	4.00	0.50	1.725	1.811	0.40	1.43	1.38	-0.04	-2.8
Classic Mild FT Kings	3.50	4.00	0.50	1.725	1.811	0.40	1.43	1.38	-0.04	-2.8
Classic Menthol FT Kings	3.50	4.00	0.50	1.725	1.811	0.40	1.43	1.38	-0.04	-2.8
Classic Ultra FT Kings	3.50	4.00	0.50	1.725	1.811	0.40	1.43	1.38	-0.04	-2.8
Gold Flake Light Kings	3.30	3.80	0.50	1.725	1.811	0.38	1.25	1.23	-0.02	-1.6
Gold Flake FT Kings	3.40	3.80	0.40	1.725	1.811	0.38	1.34	1.23	-0.11	-8.2
Silk Cut	NA	3.50	NA	1.725	1.811	0.35	NA	0.99	NA	
Longs - 5% of volumes										
Wills FT (Twin)	2.90	3.40	0.50	1.2980	1.363	0.34	1.31	1.35	0.04	3.0
Regulars - 65% of Volume	5									
Gold Flake Prm. FT	1.90	2.40	0.50	0.803	0.843	0.24	0.91	1.07	0.17	18.5
Bristol FT	1.45	1.95	0.50	0.803	0.843	0.20	0.50	0.72	0.21	42.4
Bristol FT TT	1.45	1.95	0.50	0.803	0.843	0.20	0.50	0.72	0.21	42.4
Bristol Menthol FT	1.45	1.95	0.50	0.803	0.843	0.20	0.50	0.72	0.21	42.4
Capstan FT	1.40	1.90	0.50	0.803	0.843	0.19	0.46	0.68	0.22	47.7
Wills Flake FT	1.25	1.75	0.50	0.803	0.843	0.18	0.32	0.56	0.23	72.4
Scissors FT	1.45	2.00	0.55	0.803	0.843	0.20	0.50	0.75	0.25	50.4
Scissors Menthol FT	1.45	2.00	0.55	0.803	0.843	0.20	0.50	0.75	0.25	50.4
Silk Cut	NA	2.00	NA	0.803	0.843	0.20	NA	0.75	NA	
Plains - 10% volumes										
Gold Flake	1.50	1.75	0.25	0.535	0.562	0.18	0.82	0.84	0.02	2.6
Scissors NP	1.25	1.50	0.25	0.535	0.562	0.15	0.59	0.64	0.05	7.9
Micros - 10% volumes	0.45	0.50	0.05	0.160	0.168	0.05	0.25	0.23	-0.01	-5.5%

Source: Cigarette dealers; Citi Investment Research

What is the Near-Term Taxation Risk?

Given that ITC's cigarette business now attracts taxes from two different quarters – excise (central tax) and VAT (state tax) – there are concerns that the taxation risk has increased, particularly from an increase in the VAT rate. While remaining cognizant of the potential risk, we believe that chances for an increase in FY09E VAT rate are slim. As such, it took 2 years for the empowered committee of States to build consensus at the current rate, and it is unlikely that a change could occur soon. Additionally, VAT is an "ad-valorem" tax and collections for states will continue to increase as long as gross sales realization continues to grow, irrespective of cigarette volumes. Given ITC's policy of passing on all tax hikes, it is unlikely that its gross sales could degrow in any year, which in turn should also lead to increased VAT collections for states year after year. Historically ITC's gross cigarette sales have not ever declined on a year-on-year basis, despite sharp volume declines in certain years. Thus, states may not feel a strong need to increase the actual rate of VAT. With a likely decline in volumes this year, the excise environment is also likely to remain benign next year.




Figure 3. ITC – Gross Cigarette Sales Trend (Rupees in Million)


Source: Company reports

How much will personal care business bleed?

A recent concern that we have heard is that ITC's foray into the personal care segment could result in significant cash bleed, given the presence of strong incumbents in the segment. While these concerns are not unfounded, we believe that there is a strong case that these businesses are unlikely to bleed very heavily. ITC's investments in the new FMCG segments so far have demonstrated discipline over costs and most businesses have scaled up rapidly, taking market share from strong incumbents.


According to the ITC management, all of its non-cigarette FMCG businesses (except biscuits and wafers) have already broken even. The biscuits business losses are very marginal, and it is also likely to break even in 4QFY08E. ITC's cumulative EBIT losses over the last 6 years for its non-cigarette FMCG business are about Rs10bn, against which its has scaled up its business to almost Rs20bn annually, with current growth rates in excess of 40%. The personal care business will be rolled out nationally over the next 8 quarters, and advertising and marketing expenses will be scaled up. However, according to the management, these spends are unlikely to be "excessive" and overall margin profile for the new-FMCG business segment is unlikely to deteriorate.

Figure 4. ITC Non Cigarette FMCG Business Sales and EBIT Margin Trend (Rupees in Million, Percent)



Source: Company Reports








Valuations are Attractive

ITC stock has underperformed the Sensex by almost 35% over the last 12 months and currently trades at about a 9% discount to the Sensex P/E, at its historical low. Historically, the stock has traded at an average premium of 21.4% to the Sensex, and had only on two occasions before traded at a discount to Sensex P/E. The stock currently trades at a 17xFY09E P/E against FY07-FY10E EPS CAGR of 22.4%. Over the last 3 years, ITC has traded in the range of 15x-28x 1-year forward P/E. We expect a pickup in cigarette volumes to drive valuation re-rating for the stock.






Source: DataStream, CIR

Benchmarked against the global peer group average, we believe that ITC can trade at a premium of 25%-30%, given 1) its superior EPS growth CAGR, which is at almost 1.7x peer group average, 2) India is among the fastest-growing markets for cigarettes over the long term and offers long-term sustainable volume growth opportunity, against flat to declining volumes in most developed markets and 3) additionally, ITC enjoys a 70% market share and has strong pricing power, while being insulated from foreign competition.

Figure 7. Global Tobacco Stocks P/E vs. EPS CAGR



Source: Company Reports and CIR Estimates

ITC

Company description

ITC is the leading cigarette manufacturer and marketer in India with about 74% share by value. The group is 32% owned by BAT. The company's cigarette portfolio carries strong brands such as Wills, Gold Flake, India Kings and Scissors, and two of BAT's global brands, Benson & Hedges and State Express 555. Besides tobacco, ITC operates in four other business divisions, namely agri / marine products, hotels, paper & packaging and IT. However, more than 75% of its revenue is from the cigarette business. The group has made significant investments in the hotels, paperboard and processed foods (biscuits, ready-to-eat foods, confectioneries) businesses.

Investment strategy

We rate the stock as Buy /Low Risk (1L) with a target price of Rs215. ITC stock has underperformed the Sensex by 34% over the last 12 months and by 8% over the last 3 months. The stock de-rating has been triggered by a higher than expected 12.5% VAT on cigarettes, which is likely to pare cigarette volume

growth. However, we believe that the worst is now behind us for ITC and that risk-reward is now turning favorable. While recent stock underperformance is already building in a cigarette volume decline in FY08E, we believe that margins could throw up positive surprises. Our analysis also suggests that consumer down trading from high end brands towards mid end brand (regular filters) may not have a negative impact on cigarette margins – on the contrary cigarette operating margins may surprise positively. If this scenario were to play out, then cigarette EBIT would grow higher than our estimates.

Valuation

Our target price of Rs215 is based on 20x FY09E earnings. Historically ITC has traded at an average premium of about 20% to Sensex valuations. Our target price is based on ITC's historical average premium to Sensex P/E. Over the last two years, ITC has traded in a valuation range of 15x-25x. With the overhang of VAT behind us, and with increasing optimism on the core cigarette business, we expect the stock valuations to be re-rated towards the higher end of its recent trading band, which justifies our 20x target multiple. ITC has a relatively stable earnings stream, so P/E is our primary valuation methodology.

Risks

We rate ITC as Low Risk because the company operates in branded businesses and its earnings volatility is low. With most of its earnings coming from the tobacco segment, ITC is most at risk from controls and the government's tax policy. Perceived as being a "sin" industry, the stock is prone to negative share price reactions. Other significant risks for the company are dilution in capital efficiency from investments in non-tobacco businesses and the possible acquisitions of capital intensive businesses that fail to enhance value. Upside risks to our target price include continuation of the government's policy of moderating excise taxes and a sharper-than-expected increase in dividend payout. If any of these factors has a greater impact than we expect, the stock could have difficulty achieving our target price.

Appendix A-1

Analyst Certification

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research report.

IMPORTANT DISCLOSURES



Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

Citigroup Global Markets is acting as advisor to Imperial Tobacco Group Plc in relation to its proposed takeover offer for Altadis SA.

Citigroup Global Markets is acting as advisor to Imperial Tobacco Group PIc in relation to its proposed takeover offer for Altadis SA.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Altadis, Carolina Group and Loews Corp. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Carolina Group and Loews Corp.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Altria Group, Inc., BAT, Carolina Group, Imperial Tobacco, Japan Tobacco, Loews Corp, Reynolds American, Inc. and UST.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from Imperial Tobacco, Reynolds American, Inc. and UST.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Altadis, Altria Group, Inc., BAT, Carolina Group, Gudang Garam, Imperial Tobacco, ITC, Japan Tobacco, KT&G, Loews Corp, Reynolds American, Inc. and UST in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Altria Group, Inc., BAT, Carolina Group, Imperial Tobacco, Japan Tobacco, Loews Corp, Reynolds American, Inc. and UST.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Altria Group, Inc., BAT, Carolina Group, Gudang Garam, Imperial Tobacco, ITC, Japan Tobacco, Loews Corp, Reynolds American, Inc. and UST.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Altadis, Altria Group, Inc., BAT, Carolina Group, Gudang Garam, Imperial Tobacco, ITC, Japan Tobacco, KT&G, Loews Corp, Reynolds American, Inc. and UST.

Citigroup Global Markets Inc. or an affiliate received compensation in the past 12 months from Japan Tobacco.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

9

The Firm is a market maker in the publicly traded equity securities of Altria Group, Inc., Carolina Group, Loews Corp, Reynolds American, Inc. and UST.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution								
Buy	Hold	Sell						
50%	38%	12%						
53%	55%	42%						
	50%	50% 38%						

Guide to Fundamental Research Investment Ratings:

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings are: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return).

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk rating. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underperform the relevant Sector of the Citigroup indexes.

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 14 November 2007 04:00 PM on the issuer's primary market.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Altria Group, Inc., Imperial Tobacco, KT&G, Reynolds American, Inc., Swedish Match and UST. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

This Product has been modified by the author following a discussion with one or more of the named companies.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without

notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this

11

material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the obje

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup or its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST